What should you understand before deciding?
Start with the study’s question: what is the team trying to find out, and why are you being invited? Then separate what would happen because of research from your usual care. Ask about the planned duration, visits, assessments and any treatment allocation. If randomisation or placebo is involved, ask what that means in this particular study. You should not have to infer the main plan from technical language. Explain the outline back in your own words and ask the team to correct anything you have misunderstood.
What do the risks and uncertain benefits mean for you?
Ask which risks are known, which remain uncertain and which procedures create them. A list of possible benefits does not establish that you will benefit personally. Discuss how the study could affect sleep, work, travel, support or existing care, as relevant to the protocol. Ask what monitoring is planned and whom to contact with a problem. If different study groups have different procedures, request an explanation of each. Ethics review and consent do not make research risk-free; the team needs to explain the specific uncertainties.
What are your alternatives to taking part?
Ask what care or support would remain available if you decline and who can discuss those options with you. A study appointment and a clinical consultation can have different goals, even when they take place in the same hospital. If your current clinician is involved in the study, ask them to distinguish their research and care roles. Consider discussing treatment-related questions with your usual care team. You do not need to treat a research invitation as the only path to support or as an instruction to change treatment.
Which practical and privacy sections deserve attention?
Find the parts about costs, payment, information sharing, samples, recordings and future contact. Ask which items are required and which are separate choices. Identify the responsible organisations, the study contact and any independent rights or privacy contact named in the documents. Consent to participate and the legal grounds for processing personal information are different questions. The CNIL explains this distinction within the French data-protection framework. Ask for the applicable notice instead of assuming that one research signature authorises every possible future use of your information.
Can you take time or involve someone you trust?
Ask whether you can take the information away, have another conversation or use an accessible format. If you want a supporter present, discuss what you would like them to hear and what you want kept private. Help understanding information should support your own decision. A diagnosis alone is not a reason to assume what a person can understand or decide. In Australia, the NHMRC National Statement is an ethical reference; ask the Australian study team which current arrangements apply. Do not transfer one country’s procedure to another study automatically.
What if new information appears or your choice changes?
Ask how the team will tell you about significant changes, new risks or an altered schedule, and whether further agreement will be sought. Check what stopping an activity or ending participation would involve, without changing a study medicine independently. Keep the version of the documents you received and a note of unanswered questions. You can ask for clarification after an initial discussion too. This guide cannot approve a consent form: the useful next step is to resolve the points that matter to your decision with the responsible team.